409 results about "Target antigen" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting measles virus nucleoprotein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 5E2 and 5G9 and can efficiently and specifically recognize measles virus nucleoprotein, amino acid sequences of complementary determining regions (CDR) of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting measles virus nucleoprotein. The risk of non-specific binding and cross reaction is obviously reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography, and provides a stable and reliable biological recognition tool for rapid and accurate detection of measles viruses.

The invention discloses an SaRNA vaccine for echinococcosis as well as a preparation method and application of the SaRNA vaccine. The preparation method of the SaRNA vaccine comprises the following steps: carrying out codon optimization on a modified target antigen protein through a genetic engineering technology, then assembling the modified target antigen protein with a self-replicating protein sequence, 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a plasmid, and carrying out purification to obtain the SaRNA vaccine. The preparation method comprises the following steps: constructing recombinant plasmids, sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmids to prepare SaRNA molecules, and finally wrapping the SaRNA molecules in lipid nanoparticles to form the SaRNA vaccine for the echinococcosis. Experiments prove that the SaRNA vaccine can activate humoral immunity and cellular immunity of mice at the same time, high-level EG95 specific antibodies and cytokines can be generated through low-dose immunity, and the SaRNA vaccine has wide application prospects in the aspect of preventing and / or treating the echinococcosis.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

Genetically engineered immune cells, which express at least two metabolism modulating polypeptides and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered immune cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Provided are proteins capable of engaging NK cells in cancer therapy, especially multi-specific proteins capable of binding IL 15 receptor, NKp46, target antigen of interest, and optionally Fc gamma receptor such as CD16a. Also provided are NKp46-binding proteins. The proteins have utility in the treatment of diseases, such as cancer.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different serotypes of foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by the different serotypes of foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum multivalent vaccine for foot-and-mouth disease.

The invention relates to a novel three-antigen HSV-2 subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The novel three-antigen HSV-2 subunit vaccine comprises antigens and a composite adjuvant, the antigens comprise HSV-2 gB2 envelope glycoprotein, HSV-2 gC2 envelope glycoprotein and HSV-2 gD2 envelope glycoprotein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the vaccine provided by the invention can induce a high-level neutralizing antibody, and widens targets for developing a novel multi-target antigen HSV-2 virus vaccine.

The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding fragment that specifically binds to a target antigen, such as HER2, CD20, TROP2, BCMA, or CD19. Also provided are anti-CD3 antibodies, masked anti-CD3 antibodies (including activatable anti-CD3 antibodies), anti-CD20 antibodies, and masked anti-HER2 antibodies (including activatable anti-HER2 antibodies). The antibodies described herein are useful for treatment of cancer.

A supramolecular histochemical system for staining, the system comprising chaotropic ions and a chaotropic ion complexing agent that accepts chaotropic ions as a molecular subject as a molecular guest. The chaotropic ions facilitate diffusion of probes (e.g., antibodies) into and within the tissue sample, followed by binding or dilution of the guest to the subject to facilitate binding of the antibodies to the target antigen and immunostaining or generation of histochemical signals. Alternatively, the micromolecular fluorescent probe can be used as a molecular guest to be compounded with the supramolecular subject to promote deep penetration of the supramolecular subject. A method for performing histology employs a supramolecular system with deep homogeneous histochemistry. The method is relatively fast, scalable, automated and cost effective.

The present application relates to antigen binding molecules comprising a pair of biparatomotic target binding domains, a pair of cytokine receptor binding domains and an Fc domain wherein the target binding domains concurrently bind to a target antigen and the cytokine receptor binding domains bind to a subunit of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor binding domain in the presence of the target antigen allows for selective activation of cytokine receptors and efficient mimicking of cytokine activity in a targeted manner.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting porcine epidemic diarrhea virus NP protein and application of the monoclonal antibody combination. The combination is composed of monoclonal antibodies 1E11 and 5C8 and can efficiently and specifically recognize porcine epidemic diarrhea virus NP protein, amino acid sequences of complementary determining regions of heavy chain and light chain variable regions of the combination are clear and are shown as SEQ ID NO.1-12 respectively, high specificity and high affinity of the antibodies are guaranteed, the antibody combination can effectively capture and detect target antigens, and the antibody combination can be used for detecting the porcine epidemic diarrhea virus NP protein. The risk of non-specific binding and cross reaction is reduced. The combination shows excellent sensitivity and specificity in detection platforms such as colloidal gold immunochromatography and the like, and provides a stable and reliable biological recognition tool for rapid and accurate detection of the porcine epidemic diarrhea virus.

The invention belongs to the technical field of antibody preparation, and particularly relates to a monoclonal antibody aiming at human KRT19 and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and accurately target KRT19 in cytoplasm, has good affinity in combination with KRT19, has strong anti-interference ability, effectively ensures that a detection signal is from a target antigen, has a high conformity degree between a detection result and an actual situation, and has good application prospects. A powerful tool is provided for high-sensitivity and high-precision detection of the KRT19 in tissues and / or cells, deep research on functions and regulation mechanisms of the KRT19 in cytoskeleton, epithelial tissue and tumor biology is facilitated, and the kit has important application prospects.

The invention provides a kit for detecting an AChR antibody based on a CBA method. The kit comprises skeletal muscle primary cells of fetal mice and skeletal muscle primary cells of adult mice. The skeletal muscle primary cells of fetal rats and adult rats obtained through primary cell isolation culture can naturally express fetal and adult AChR target antigens respectively, and compared with a traditional cell transfection technology, the skeletal muscle primary cells of fetal rats and adult rats obtained through the method have natural AChR protein expression, and can be used for preparing the skeletal muscle primary cells of fetal rats and adult rats. The problems of high cytotoxicity and low detection sensitivity caused by transient expression of five subunits and polymeric protein in traditional cell transfection are successfully avoided, and the detection sensitivity of the AChR antibody is effectively improved.

The invention relates to a novel HSV-2 three-antigen recombinant protein vaccine composition and application thereof, and belongs to the technical field of biology. The vaccine composition comprises an antigen and a composite adjuvant, the antigen is HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein, and the composite adjuvant is CpG oligonucleotide and an aluminum adjuvant; the amino acid sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 1, and the nucleotide sequence of the HSV-2 gC2-gD2-gE2 three-antigen tandem recombinant protein is as shown in SEQ ID NO. 2. The time cost and the economic cost in the protein preparation process are greatly reduced, and compared with an original trivalent combination vaccine, the trivalent combination vaccine can induce the level of specific antibodies generated by mice and the virus neutralizing capacity not to be reduced, so that a brand new thought is provided for developing advanced HSV-2 virus vaccines with multiple target antigens, and the trivalent combination vaccine is worthy of popularization and application. Meanwhile, the invention also provides a safe and effective HSV-2 virus candidate vaccine.

The invention relates to the technical field of genetic engineering, in particular to a self-assembled protein cage nanoparticle epitope insertion site and application thereof in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between the 124 -125 amino acid of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 124 -125 amino acid is replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

Two plasmids are transformed in the bacterium, one plasmid is a gene editing plasmid which is used for expressing CRISPR / Cas9 gene editing tools in the bacterium, the sgRNA sequence is shown in SEQ ID NO.1, and the other plasmid is an X174E-CKS9 expression plasmid which is used for expressing targeting peptide shown in SEQ ID NO.2 and IPTG (isopropyl-beta-d-thiogalactoside) induced expression splitting gene X174E in the bacterium. The invention further discloses a cracking vesicle obtained after induction of the engineering bacterium and application of the cracking vesicle. CKS9-loaded lysing vesicles with M cell targeting are generated in situ, and a gene editing tool is transferred to antigen presenting cells by using the characteristic that the M cells can completely transfer antigens to lymphatic follicles. Compared with a strategy of mannose modification and other targeted antigen-presenting cells, the method has the advantages that the targeting property is more accurate, and a new choice is provided for the antigen-presenting cells of targeted intestinal tracts.

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

The invention belongs to the technical field of biological medicine, and discloses an anti-CD39 nano antibody and application thereof. The anti-CD39 nano antibody has an amino acid sequence as shown in SEQ ID NO.1, 5, 9, 13, 17, 21 or 25. The anti-CD39 nano antibody of some examples has good antigen specificity, can be effectively combined with a target antigen CD39, and can effectively block or inhibit the hydrolysis of ATP (adenosine triphosphate) by the CD39, so that the depletion of T cells by a tumor microenvironment is effectively inhibited, and the curative effect of tumor immunotherapy is expected to be improved. The anti-CD39 nano antibody of some examples of the invention can further improve the curative effect of T cell immunotherapy related to CAR-T, TCR-T, TIL, TAL, NK, CIK and the like.

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an EC50 of about 10 nM or less, and / or are capable of promoting complement deposition on the target antigen with an EC50 of about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and / or therapeutically beneficial.

The invention relates to screening methods. In particular, it relates to a method of identifying a functional TCR from a library of particles, which displays a plurality of different T cell receptors (TCRs). The method may comprise a) exposing the library of particles to a target antigen to identify TCRs that bind to the target antigen, b) transfecting a plurality of T cells with nucleic acid encoding TCRs identified in step (a), c) exposing the plurality of transfected cells to the target antigen, and d) selecting cells having TCR activity in the presence of the target antigen. Transfection of the T cells is such that each T cell comprises a nucleic acid encoding a single TCR from the library of particles, the nucleic acid is integrated into the genome of the T cell at a single identical pre-defined locus, and the TCR is in a single chain format and comprises an alpha chain variable domain, a beta cain variable domain and a constant domain. The T cells do not express endogenous TCR. A T-cell comprising a recombinase mediated landing pad, wherein the T cell constitutively expresses TCR constant domain and does not express endogenous TCR, is also claimed.

The application discloses a detection method of cell surface antigens and application thereof, and relates to the detection field. The detection method of cell surface antigens comprises the following steps: mixing liposome-treated cells to be detected with capture microspheres and fluorescent microspheres, detecting the fluorescence intensity, and analyzing the expression of cell surface antigens. The surface of the capture microspheres is coated with a first antibody against a specific antigen on the surface of target cells. The surface of the fluorescent microspheres is coated with a second antibody against a target antigen on the surface of target cells. The detection method has low cost and can be used for directly quantitatively and qualitatively analyzing the expression of surface antigens of specific types of cells.

To provide a targeting moiety-drug conjugate that is biodegradable and biocompatible and exhibits high drug load as well as strong binding to a target antigen.SOLUTION: Provided is a conjugate comprising a targeting moiety and one or more linker-drug moieties covalently bonded to the targeting moiety, each linker-drug moiety including a multifunctional linker that connects the targeting moiety to one or more drug units through intermediacy of a releasable assembly unit for each drug unit and connects a hydrophilic group to the drug units of each linker-drug moiety, the releasable assembly units being capable of releasing a free drug in proximity to a target site targeted by the targeting moiety, the multifunctional linker comprising a peptide moiety between the targeting moiety and the hydrophilic group, and the peptide moiety includes at least two amino acids.SELECTED DRAWING: Figure 1

The application discloses an mRNA vaccine sequence design system and method based on a large language model intelligent agent, and the mRNA vaccine sequence design system based on the large language model intelligent agent comprises a user interaction and task analysis module, a task planning and intelligent agent scheduling module, an RNA design skill library and skill description module, a multi-target evaluation and closed-loop optimization module and a data and model management module. The application integrates a large language model and various mRNA sequence analysis and optimization tools, automatically completes mRNA vaccine sequence generation, evaluation and optimization for a target antigen in a computer environment, is suitable for candidate sequence design and screening of a preventive or therapeutic mRNA vaccine, improves design efficiency, and reduces the degree of dependence on manual experience and manual script arrangement.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

The utility model discloses a paraffin section immunohistochemical staining box, which belongs to the technical field of staining boxes and is characterized by comprising a staining box body, the left side of the staining box body is fixedly connected with a preheating mechanism, the left side of the preheating mechanism is fixedly connected with a temperature control mechanism, and the preheating mechanism heats a placing plate through a heating plate. The reagent in the placing groove is further preheated, so that the reagent is at a proper temperature when being in contact with the paraffin section, the binding reaction of the reagent and a target antigen is accelerated, the time required for dyeing is shortened, and the dyeing efficiency is effectively improved; the temperature in the placing groove is detected in real time by a detection head of the temperature control mechanism through a temperature measuring hole; according to the preheating device, the temperature sensor is arranged on the heating plate and transmits a temperature signal to the temperature sensor, the temperature sensor transmits the signal to the microcontroller, and the microcontroller accurately controls the heating power of the heating plate according to a preset temperature value, so that accurate regulation and control of the preheating temperature are realized.

Embodiments of the present disclosure disclose an antigen-antibody binding conformation optimization method and device based on iterative closest point. A specific embodiment of the method comprises: obtaining a coarse-grained antibody file and a coarse-grained antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. The embodiment can improve the accuracy of the antibody conformation.

The invention discloses a fusion protein linked with CD40-expressing cells containing APC and target specific T cells and application thereof, CD40L and other elements combined with CD40 are fused with target antigens specifically recognized by molecules in cells such as CAR-T or TCR-T to form a bifunctional protein, the DC maturation of the CD40L and other elements combined with CD40 can be enhanced, and meanwhile, the CD40L and other elements combined with CD40 can be combined with the target antigens specifically recognized by the molecules in the cells such as CAR-T or TCR-T to form the bifunctional protein, so that the CD40L and other elements combined with CD40 can be combined with the target antigens specifically recognized by the molecules in the cells. The target antigen is effectively delivered to the surface of the DC, so that the activation effect of the DC on cells such as CAR-T or TCR-T is enhanced, and particularly, the effect of enhancing the functions such as terminal amplification and reverse depletion of the cells such as CAR-T or TCR-T is remarkable.

The present invention relates to agents and methods for targeted delivery of a payload to a cell. The payload comprises various molecules, such as therapeutic or diagnostic agents, in particular toxins, immunomodulators or radiodiagnostic agents. In some embodiments, the invention relates to providing a subject with a compound comprising a payload moiety and at least two tags (tag conjugates) and a compound (docking compound) that binds to the tags of the tag conjugates and a target antigen (e.g., a cell surface antigen on a target cell).